Search
Oxford, UK based Sitryx has been busy lately with a deal announced with Boehringer Ingelheim, and its lead program targeting PKM2 in the clinic for atopic dermatitis
CEO Iain Kilty talks about Sitryx's approach to modulating inflammation and shares updates on the Boehringer deal, a program that has been received back from Lilly, and the company's clinical activities.
Jul 20
Oxford Science Park based Sitryx aims to be a leader immunometabolism - a deal with Lilly has been validating
CEO Iain Kilty describes the keys to intervening in cell metabolism, and discusses pipeline assets such as a PKM2 for atopic dermatitis...
Sep 17, 2024
.png){kind=logo}